Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company is experiencing short-term pressure on performance due to strategic adjustments and a weak downstream market in biomedicine, with expectations for profit recovery in the future [2][3] - The company has shifted its focus towards enterprise clients, impacting new order acquisition, and is currently undergoing a strategic transformation [2] - The company is investing in new laboratory facilities across multiple regions to enhance its comprehensive testing capabilities [3] Financial Performance Summary - In the first half of 2024, the company achieved total revenue of 730 million yuan, a year-on-year decrease of 39%, and a net profit attributable to shareholders of -170 million yuan, a year-on-year decline of 284% [2] - The gross profit margin for the first half of 2024 was 28.8%, down 15.7 percentage points year-on-year, while the net profit margin was -23.6%, down 31.5 percentage points year-on-year [3] - The company has adjusted its earnings forecasts for 2024-2026 to 0.08 billion yuan (previously 3.0 billion), 1.7 billion yuan (previously 3.8 billion), and 2.7 billion yuan (previously 4.6 billion), respectively [3] Business Segment Performance - Revenue from the life sciences and environmental health segment was 500 million yuan, a decrease of 45% year-on-year, while revenue from the automotive and other consumer goods segment was 130 million yuan, an increase of 4% year-on-year [2] - The company is currently facing challenges in its traditional business client structure and is experiencing losses due to fixed costs from newly established laboratories [2][3] Market Data - The company's closing price is 6.46 yuan, with a market capitalization of approximately 3.53 billion yuan [4] - The price-to-earnings ratio (P/E) based on the latest diluted earnings per share is projected to be 433.85 for 2024 [3][12]

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2024, representing a year-on-year increase of 15%[8]. - The net profit attributable to shareholders for the same period was RMB 80 million, up 20% compared to the previous year[8]. - Future guidance indicates a projected revenue growth of 18% for the full year 2024[8]. - The company's operating revenue for the reporting period was ¥728,074,335.53, a decrease of 38.67% compared to the same period last year[14]. - The net profit attributable to shareholders was -¥171,373,267.55, representing a decline of 283.62% year-on-year[14]. - The net cash flow from operating activities was -¥86,273,322.94, down 158.67% from the previous year[14]. - The company's gross profit margin for the life sciences and health environmental segment was 20.54%, down 21.43% year-on-year, with revenue declining by 45.34%[53]. - The company reported a significant focus on cash dividends, with a minimum cash dividend ratio of 80% during mature stages without major capital expenditure arrangements[120]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% growth in that region by the end of 2025[8]. - The company is exploring acquisition opportunities to enhance its service offerings and market share[8]. - A strategic acquisition of a local competitor is expected to be finalized by Q4 2024, which will enhance the company's service offerings[115]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by the end of 2025[114]. Research and Development - The company is investing RMB 30 million in R&D for new technologies related to environmental testing[8]. - Research and development expenses amounted to ¥85,110,921.08, down 17.04% from ¥102,597,481.82, mainly due to reduced sales collections[52]. - The company launched an AI target prediction and virtual screening project in collaboration with the Shanghai Institute of Materia Medica, enhancing drug quality assurance in veterinary medicine[46]. - Research and development expenses for the first half of 2024 were CNY 15.47 million, down from CNY 20.63 million in the same period of 2023, indicating a reduction of approximately 25.5%[170]. Operational Challenges - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[2]. - The company is facing risks from intensified market competition, particularly from state-owned and foreign testing institutions, which may impact its operational performance[73]. - The company reported a decline in overall gross profit due to a shift in customer structure and increased competition in the biopharmaceutical CRO/CDMO sector, leading to losses[45]. - The company acknowledges the potential impact of adverse changes in industry policies and standards on its business development[73]. Corporate Governance and Shareholder Relations - The company has a strong commitment to protecting the rights of shareholders and creditors, ensuring transparency and communication through various channels[100]. - The company has established a "Quality Return Dual Improvement" action plan to enhance investor confidence and maintain long-term sustainable development[78]. - The company held two temporary shareholder meetings and one annual shareholder meeting in 2024, with investor participation rates of 64.39%, 64.38%, and 64.50% respectively[83][84][85]. - The company plans to implement a shareholder dividend return plan for the next three years (2024-2026) to ensure stable profit distribution[80]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including promoting green office practices and encouraging employees to use public transportation[98]. - The company emphasizes social responsibility, actively participating in public welfare and charity initiatives while ensuring compliance with relevant laws and regulations[99]. - PONY Group actively participated in charitable activities, donating materials to various charitable organizations and welfare institutions across multiple cities, including Shenzhen and Shanghai[106]. - The company has established a comprehensive environmental protection management system, including regulations and guidelines for energy management and carbon emissions[104]. Financial Management and Investments - The total amount of funds raised by the company was RMB 1,227,843,967.82 after deducting fees[60]. - The company has cumulatively invested RMB 70,598.31 million of the raised funds as of the reporting period[60]. - The company reported a fair value change of financial assets amounting to RMB 532,036,981.91 at the end of the reporting period[55]. - The company has a long-term commitment to normal operations regarding share repurchase measures[119]. Compliance and Regulatory Matters - The company has maintained compliance with the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[192]. - The company has not encountered any issues or other circumstances regarding the use of raised funds[65]. - The company has not reported any changes in the board of directors or supervisory board during the reporting period[85]. - The company has not engaged in any significant related party transactions during the reporting period[131].

证券代码：300887 证券简称：谱尼测试 公告编号：2024-064 谱尼测试集团股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 谱尼测试集团股份有限公司（以下简称"公司"）第五届董事会第十四次 会议于 2024 年 8 月 28 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开。本次会议的通知已 于 2024 年 8 月 16 日以专人送达的方式发出。会议由董事长宋薇女士召集和主持， 会议应出席董事 6 人，实际出席董事 6 人，公司监事列席了会议。本次会议的召 集、召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 出席会议的董事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年半年度报告〉全文及其摘要的议案》 募集资金存放和使用违规的情形，不存在变相改变募集资金投向和损害股东利益 的情况；公司编制的《2024 年半年度募集资金存放与使用情况的专项报告》内 容真实、准确、 ...

谱尼测试集团股份有限公司2024年半年度 非经营性资金占用及其他关联资金往来情况汇总表 谱尼测试集团股份有限公司2024年半年度 非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 上市公司的子公司 | 内蒙古谱尼测试技 | 全资子公司 | 应收账款 | 518.32 | 141.94 | 261.87 | | 398.39 | 经营往来 | 经营性往来 | | 及其附属企业 | 术有限公司 | | | | | | | | | | | 上市公司的子公司 | 郑州国准检测技术 | 全资子公司 | 应收账款 | 273.94 | 20.77 | | - | 294.71 | 经营往来 | 经营性往来 | | 及其附属企业 | 有限公司 | | | | | | | | | | | 上市公司的子公司 | 武汉谱尼科技有限 公司 | 全资子公司 | 应收账款 | 268.57 | 47.62 | | - | 316.19 | 经 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-065 二、监事会会议审议情况 出席会议的监事对各项议案进行了认真审议并做出了如下决议： （一）审议通过《关于〈2024 年半年度报告〉全文及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司《2024 年半年度报告》全文 及其摘要的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 内容详见同日刊登于中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）的相关公告。 谱尼测试集团股份有限公司 第五届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 谱尼测试集团股份有限公司（以下简称"公司"）第五届监事会第十三次 会议于 2024 年 8 月 28 日下午在北京市海淀区中关村环保科技示范园锦带路 66 号院 1 号楼谱尼测试大厦 207 会议室以现场表决的方式召开 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-069 谱尼测试集团股份有限公司 关于部分募集资金投资项目延期的公告 本次部分募投项目延期未改变公司募集资金的用途和投向，根据《深圳证 券交易所创业板股票上市规则（2024 年修订）》（以下简称"《创业板股票上 市规则》"）、《深圳证券交易所创业板上市公司自律监管指引第 2 号——创 业板上市公司规范运作（2023 年 12 月修订）》（以下简称"《规范运作指 引》"）、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求（2022 年修订）》等相关规定以及公司股东大会之授权，上述事项无需 提交公司股东大会审议。具体情况公告如下： 一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会《关于同意谱尼测试集团股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2022〕210号）核准，公司于 2022 年 3 月 22 日向特定对象发行股票总数量为22,418,670股，发行价格为55.30元/ 股，实际募集资金总额为人民币1,239,752,451.00元，扣除本次发行费用人民 币11,908,483.18元 ...

证券代码： 300887 证券简称：谱尼测试 公告编号： 2024-071 谱尼测试集团股份有限公司 关于举行2024年半年度业绩说明会的公告 欢迎广大投资者积极参与！ 特此公告。 谱尼测试集团股份有限公司 董 事 会 2024 年 8 月 28 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 谱尼测试集团股份有限公司(以下简称"公司")《2024年半年度报告》已于2024年8月29日 （星期四）披露，为使投资者进一步了解公司的财务状况、经营情况及公司发展规划，公司将 于 2024 年 9 月 5 日(星期四) 15：00-17：00 在全景网举行 2024 年半年度业绩说明会，本 次业绩说明会将采用网络远程方式举行，投资者可登录全景网"投资者关系互动平台" (https://ir.p5w.net/ )参与本次说明会。 出席本次业绩说明会的人员有：公司董事长宋薇女士；董事、总经理张英杰先生；董事、 董事会秘书李小冬先生；副总经理、财务负责人吕琦先生；独立董事朱玉杰先生、独立董事胡 文祥先生、保荐代表人刘晓宁先生、保荐代表人王禹女士。 为充分尊重投资者、提升 ...

证券代码：300887 证券简称：谱尼测试 公告编号：2024-068 谱尼测试集团股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自 律监管指南第 2 号——公告格式（2023 年修订）》的相关规定，本公司就截至 2024 年 6 月 30 日止的募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 1、实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于谱尼测试集团股份有限公司向特定对象发行股票注册的 批复》（证监许可〔2022〕210 号）同意，谱尼测试向特定对象发行不超过 41,106,171 股新股 募集资金用于谱尼测试集团山东总部大厦暨研发检测中心项目、谱尼西北总部大厦（西安）项 目和补充流动资金项目。公司 ...

北京德恒律师事务所 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 关于谱尼测试集团股份有限公司 北京德恒律师事务所 2024 年第四次临时股东大会的法律意见 北京德恒律师事务所 关于 谱尼测试集团股份有限公司 2024 年第四次临时股东大会的 法律意见 德恒 01G20200488-19 号 致：谱尼测试集团股份有限公司 北京德恒律师事务所接受谱尼测试集团股份有限公司（以下简称"公司"）委 托，指派彭闳律师、刘元军律师（以下简称"本所律师"）出席公司 2024 年第四 次临时股东大会（以下简称"本次股东大会"），对本次股东大会的合法性进行见 证并出具法律意见。 本法律意见根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）等现行有效的法律、法规、规范性文件以及《谱 尼测试集团股份有限公司章程》（以下简称"《公司章程》"）的规定而出具。 为出具本法律意见，本所律师审查了公司本次股东大会的有关文件 ...

2024 年第四次临时股东大会决议公告 谱尼测试集团股份有限公司 证券代码：300887 证券简称：谱尼测试 公告编号：2024-063 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 （1）现场会议时间：2024 年 8 月 19 日（星期一）下午 15:00 （2）网络投票时间：2024 年 8 月 19 日 通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 8 月 19 日 9:15-9:25，9:30- 11:30 和 13:00-15:00。 通过深圳证券交易所互联网投票系统进行网络投票的时间为 2024 年 8 月 19 日上午 9:15 至下午 15:00 期间的任意时间。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、谱尼测试集团股份有限公司（以下简称"公司"）2024 年第四次临时股东大会通知于 2024 年 8 月 2 日在中国证监会指定信息披露网站巨潮资讯网（http://www.cninfo.com.cn） 上以公告形式发出，本次股东大会采取现 ...